174 related articles for article (PubMed ID: 37847430)
21. Impact of pre-treatment with somatostatin analogs on surgical management of acromegalic patients referred to a single center.
Bacigaluppi S; Gatto F; Anania P; Bragazzi NL; Rossi DC; Benvegnu G; Nazzari E; Spaziante R; Giusti M; Ferone D; Zona G
Endocrine; 2016 Mar; 51(3):524-33. PubMed ID: 25982150
[TBL] [Abstract][Full Text] [Related]
22. A prospective analysis of 151 cases of patients with acromegaly operated by one neurosurgeon: a follow-up of more than 23 years.
Abbassioun K; Amirjamshidi M; Mehrazin A; Khalatbary I; Keynama M; Bokai H; Abdollahi M
Surg Neurol; 2006 Jul; 66(1):26-31; discussion 31. PubMed ID: 16793431
[TBL] [Abstract][Full Text] [Related]
23. Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs.
Petrossians P; Borges-Martins L; Espinoza C; Daly A; Betea D; Valdes-Socin H; Stevenaert A; Chanson P; Beckers A
Eur J Endocrinol; 2005 Jan; 152(1):61-6. PubMed ID: 15762188
[TBL] [Abstract][Full Text] [Related]
24. Stereotactic radiosurgery for acromegaly: outcomes by adenoma subtype.
Lee CC; Vance ML; Lopes MB; Xu Z; Chen CJ; Sheehan J
Pituitary; 2015 Jun; 18(3):326-34. PubMed ID: 24925503
[TBL] [Abstract][Full Text] [Related]
25. Metabolic glucose status and pituitary pathology portend therapeutic outcomes in acromegaly.
Cheng S; Al-Agha R; Araujo PB; Serri O; L Asa S; Ezzat S
PLoS One; 2013; 8(9):e73543. PubMed ID: 24039977
[TBL] [Abstract][Full Text] [Related]
26. Preoperative lanreotide treatment for GH-secreting pituitary adenomas: effect on tumour volume and predictive factors of significant tumour shrinkage.
Lucas T; Astorga R; Catalá M;
Clin Endocrinol (Oxf); 2003 Apr; 58(4):471-81. PubMed ID: 12641631
[TBL] [Abstract][Full Text] [Related]
27. An audit of treatment outcome in acromegalic patients attending our center at Bergamo, Italy.
Attanasio R; Montini M; Valota M; Cortesi L; Barbò R; Biroli F; Tonnarelli G; Albizzi M; Testa RM; Pagani G
Pituitary; 2008; 11(1):1-11. PubMed ID: 17690987
[TBL] [Abstract][Full Text] [Related]
28. Preoperative growth hormone response to thyrotropin-releasing hormone and oral glucose tolerance test in acromegaly: a retrospective evaluation of 50 patients.
De Marinis L; Mancini A; Bianchi A; Gentilella R; Valle D; Giampietro A; Zuppi P; Anile C; Maira G; Giustina A
Metabolism; 2002 May; 51(5):616-21. PubMed ID: 11979395
[TBL] [Abstract][Full Text] [Related]
29. Management of growth hormone-secreting pituitary adenomas causing acromegaly: a practical review of surgical and multimodal management strategies for neurosurgeons.
Cheok SK; Carmichael JD; Zada G
J Neurosurg; 2024 May; 140(5):1285-1294. PubMed ID: 37948697
[TBL] [Abstract][Full Text] [Related]
30. Outcomes after a purely endoscopic transsphenoidal resection of growth hormone-secreting pituitary adenomas.
Campbell PG; Kenning E; Andrews DW; Yadla S; Rosen M; Evans JJ
Neurosurg Focus; 2010 Oct; 29(4):E5. PubMed ID: 20887130
[TBL] [Abstract][Full Text] [Related]
31. Percent reduction of growth hormone levels correlates closely with percent resected tumor volume in acromegaly.
Schwyzer L; Starke RM; Jane JA; Oldfield EH
J Neurosurg; 2015 Apr; 122(4):798-802. PubMed ID: 25423276
[TBL] [Abstract][Full Text] [Related]
32. The multimodal management of GH-secreting pituitary adenomas: predictive factors, strategies and outcomes.
Buliman A; Tataranu LG; Ciubotaru V; Cazac TL; Dumitrache C
J Med Life; 2016; 9(2):187-92. PubMed ID: 27453753
[TBL] [Abstract][Full Text] [Related]
33. Postoperative GH and Degree of Reduction in IGF-1 Predicts Postoperative Hormonal Remission in Acromegaly.
Cardinal T; Collet C; Wedemeyer M; Singer PA; Weiss M; Zada G; Carmichael JD
Front Endocrinol (Lausanne); 2021; 12():743052. PubMed ID: 34867787
[TBL] [Abstract][Full Text] [Related]
34. Endoscopic Endonasal Approach to the Growth Hormone-Secreting Pituitary Adenomas: Endocrinologic Outcome in 68 Patients.
Taghvaei M; Sadrehosseini SM; Ardakani JB; Nakhjavani M; Zeinalizadeh M
World Neurosurg; 2018 Sep; 117():e259-e268. PubMed ID: 29902603
[TBL] [Abstract][Full Text] [Related]
35. Predictors of postoperative biochemical remission in lower Knosp grade growth hormone-secreting pituitary adenomas: a large single center study.
Zhang S; Chen J; Yao S; Akter F; Wang Z; Hu B; Zhu D; Duan C; Chen W; Zhu Y; Wang H; Mao Z
J Endocrinol Invest; 2023 Mar; 46(3):465-476. PubMed ID: 36125731
[TBL] [Abstract][Full Text] [Related]
36. Neuroendocrine tumors secreting growth hormone-releasing hormone: Pathophysiological and clinical aspects.
Gola M; Doga M; Bonadonna S; Mazziotti G; Vescovi PP; Giustina A
Pituitary; 2006; 9(3):221-9. PubMed ID: 17036195
[TBL] [Abstract][Full Text] [Related]
37. Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study.
Plöckinger U; Quabbe HJ
Acta Neurochir (Wien); 2005 May; 147(5):485-93; discussion 493. PubMed ID: 15806331
[TBL] [Abstract][Full Text] [Related]
38. Radiosurgery of growth hormone-producing pituitary adenomas: factors associated with biochemical remission.
Pollock BE; Jacob JT; Brown PD; Nippoldt TB
J Neurosurg; 2007 May; 106(5):833-8. PubMed ID: 17542527
[TBL] [Abstract][Full Text] [Related]
39. Long-term changes in serum IGF-1 levels after successful surgical treatment of growth hormone-secreting pituitary adenoma.
Shin MS; Yu JH; Choi JH; Jung CH; Hwang JY; Cho YH; Kim CJ; Kim MS
Neurosurgery; 2013 Sep; 73(3):473-9; quiz 479. PubMed ID: 23728452
[TBL] [Abstract][Full Text] [Related]
40. Endoscopic Endonasal Approach to Giant Pituitary Adenomas: Surgical Outcomes and Review of the Literature.
Rahimli T; Hidayetov T; Yusifli Z; Memmedzade H; Rajabov T; Aghayev K
World Neurosurg; 2021 May; 149():e1043-e1055. PubMed ID: 33524611
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
